Selective Laser Trabeculoplasty (SLT) is a cutting-edge and non-invasive laser procedure that has become a cornerstone in the management of open-angle glaucoma, a prevalent condition characterized by increased intraocular pressure. Unlike traditional trabeculoplasty procedures, SLT selectively targets specific pigmented cells in the trabecular meshwork using a low-energy laser, sparing surrounding tissues. By stimulating these cells, SLT enhances the drainage of aqueous humor, promoting better fluid outflow and reducing intraocular pressure. This outpatient procedure is well-tolerated and can be repeated if necessary, offering a versatile and effective solution for patients seeking an alternative or adjunct to glaucoma medications.
Patients undergoing Selective Laser Trabeculoplasty typically experience minimal discomfort, and the recovery period is brief, making it an attractive option for those with busy lifestyles. The precision of SLT and its ability to achieve pressure reduction with fewer side effects than traditional treatments make it a valuable tool in the ophthalmologist's toolkit. As part of a comprehensive glaucoma management strategy, SLT provides a targeted and efficient approach to controlling intraocular pressure, ultimately preserving optic nerve health and helping to prevent the progression of glaucomatous damage.